News | ECG Monitoring Services | May 08, 2018

BardyDx CAM Ambulatory ECG Monitor Patch Detects More Arrhythmias in Head-to-Head Study

Seven-day monitoring period reveals greater ECG signal clarity compared to Zio XT patch

BardyDx CAM Ambulatory ECG Monitor Patch Detects More Arrhythmias in Head-to-Head Study

May 8, 2018 — Bardy Diagnostics Inc. (BardyDx) announced that the American Heart Journal has published the results of a head-to-head comparison of two patch-based arrhythmia monitoring systems. The study, "Comparison of two ambulatory patch ECG monitors: The benefit of the P-wave and signal clarity,"[1] concluded the BardyDx CAM single-channel patch ambulatory ECG monitor (AEM), designed specifically to enhance P-wave detection, identified significantly more arrhythmias and resulted in better, more informed clinical decision-making over the iRhythm Zio XT patch.

In the prospective time-paired comparative study — led by electrophysiologist Robert Rho, M.D., FHRS, FACC — 30 patients simultaneously wore a pectorally-placed arrhythmia monitoring patch (iRhythm Technologies, Zio XT patch) and a P-wave centric arrhythmia monitoring patch (Bardy Diagnostics, CAM patch) placed over the sternum with the intent of recording for 7 days. At the end of the monitoring period, the patches were removed at the same visit. The outcome measures were to compare diagnostic yield, ECG signal clarity, ease of use and comfort, and an assessment of differences in clinical decision-making based upon each device's rhythm diagnosis.

The study evaluated the differences in specific rhythm diagnosis and ECG clarity between the two commercially available patch AEMs. The CAM patch identified more arrhythmias (particularly atrial tachycardia, atrial flutter and non-sustained VT) than the Zio XT patch in contrast to atrial fibrillation, where both monitors performed adequately. ECG clarity was ranked as "high" in all CAM reports compared to the Zio XT reports (100 percent versus 16 percent, p<0.001). Both devices were considered user-friendly; however, the CAM patch was observed to be slightly easier to attach and remove, more stable and associated with less skin reaction. It was found that the superior signal clarity provided by the CAM patch may result in more informed clinical decisions in over a third of the patients.

Rho commented, "Most innovations in AEMs have focused on increased monitoring duration. Although duration of recording improves arrhythmia diagnosis, a very important factor is the clarity of the ECG recording. AEM diagnostics and ECG clarity vary with electrode location, signal noise, signal processing technology and electronic design. The clarity of an ECG signal is important in providing the ability to see P-waves during a recorded arrhythmia. The ability to accurately detect P-waves during an arrhythmia event allows physicians to make a more specific and confident rhythm diagnosis. This study demonstrates that significant differences in diagnostic yield exist between these two seemingly similar patch ambulatory ECG monitors applied during the same 7-day monitoring period and that these differences can impact clinical decision making."  

The patch-to-patch comparison study builds on a study conducted by Warren Smith, MBChB, comparing the BardyDx CAM patch and a traditional Holter monitor, also in a simultaneous, paired assessment. That study demonstrated that the BardyDx CAM "resulted in a significantly improved rhythm diagnosis and avoided inaccurate diagnoses made by the standard three-channel Holter monitor" on a time-controlled basis.

The updated version of the CAM is called the Carnation. 

For more information: www.bardydx.com

 

Reference:

1. Robert Rho, Mark Vossler, Susan Blancher, et al. Comparison of two ambulatory patch ECG monitors: The benefit of the P-wave and signal clarity. American Heart Journal. DOI: https://doi.org/10.1016/j.ahj.2018.03.022

 

Related Content

Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
AHA Statement Warns Hookah Smoking May Harm the Heart
News | Cardiac Diagnostics | March 08, 2019
Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...
Overlay Init